ITM Medical

ITM Isotope Technologies Munich is a leading radiopharmaceutical company dedicated to developing, producing, and globally distributing high-quality diagnostic and therapeutic radiopharmaceuticals and radioisotopes for cancer treatment. The company's flagship product is EndolucinBeta (n.c.a. 177Lu-chloride), a precursor used in targeted radionuclide therapy that serves as a critical component for various approved and experimental cancer treatments. ITM is advancing a proprietary pipeline of targeted radiotherapies, most notably ITM-11, which is currently in Phase 3 clinical trials for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). By combining its robust manufacturing capabilities with innovative medical research, ITM aims to provide more precise and effective treatment options for patients with hard-to-treat cancers. The company maintains a global supply network and collaborates with major pharmaceutical players to expand the reach of radioligand therapy.